Posted on June 8, 2018 by Sitemaster
We have previously reported data from the 2-year follow-up of the patients participating in the PCM301 trial of vascular targeted phototherapy (VTP) — a form of prostate hemiablation — compared to active surveillance in the treatment of low-risk, localized prostate cancer. New data at 4 years of follow-up have now been published in the Journal of Urology. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, outcome, photodynamic, surveillance, targeted, TOOKAD, vascular, VTP | 3 Comments »
Posted on May 17, 2018 by Sitemaster
The results of the so-called PRECISION trial were just published in the New England Journal of Medicine this morning. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, MRI, outcome, precision, risk, targeted, trial | 3 Comments »
Posted on May 1, 2018 by Sitemaster
In the first trial ever to randomly assign patients to extreme hypofractionation, primary radiation therapy delivered in just seven treatments had the same effectiveness and safety as 39 treatments. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: 3D-CRT, body, conventional, outcome, radiation, randomized, SBRT, stereotactic, trial | 2 Comments »
Posted on April 20, 2018 by Sitemaster
A presentation at the upcoming annual meeting of the American Urological Association (AUA) will provide data on outcomes of men initially managed on active surveillance at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York over the past 17 years. … READ MORE…
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, outcome, protocol, rigor, risk, surveillance | 2 Comments »
Posted on April 20, 2018 by Sitemaster
In October last year we had expressed the hope that data from the Men’s Eating and Living (MEAL) study would be presented at a major medical meeting this year. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, outcome, surveillance, trial | Leave a comment »
Posted on April 17, 2018 by Sitemaster
One paper to be presented at the upcoming annual meeting of the American Urological Association (AUS) gives results from treatment with a 3-month dose of androgen deprivation therapy (ADT) for men with low-risk prostate cancer compared to standard active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: ac tive, ADT, leuprolide, low risk, outcome, short-term, surveillance, trial | 9 Comments »
Posted on April 11, 2018 by Sitemaster
According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, lutetium-177, outcome, Phase III, pivotal, PSMA-617, safety, trial | 4 Comments »
